Characteristics of Artificial Intelligence Clinical Trials in the Field of Healthcare: A Cross-Sectional Study on ClinicalTrials.gov

Abstract

Artificial intelligence (AI) has driven innovative transformation in healthcare service patterns, despite a lack of understanding of its performance in clinical practice. We conducted a cross-sectional analysis of AI-related trials in healthcare based on ClinicalTrials.gov, intending to investigate the trial characteristics and AI’s development status. Additionally, the Neo4j graph database and visualization technology were employed to construct an AI technology application graph, achieving a visual representation and analysis of research hotspots in healthcare AI. A total of 1725 eligible trials that were registered in ClinicalTrials.gov up to 31 March 2022 were included in this study. The number of trial registrations has dramatically grown each year since 2016. However, the AI-related trials had some design drawbacks and problems with poor-quality result reporting. The proportion of trials with prospective and randomized designs was insufficient, and most studies did not report results upon completion. Currently, most healthcare AI application studies are based on data-driven learning algorithms, covering various disease areas and healthcare scenarios. As few studies have publicly reported results on ClinicalTrials.gov, there is not enough evidence to support an assessment of AI’s actual performance. The widespread implementation of AI technology in healthcare still faces many challenges and requires more high-quality prospective clinical validation.

Harnessing the Power of Artificial Intelligence in Cleft Lip and Palate: An In-Depth Analysis from Diagnosis to Treatment, a Comprehensive Review

“…Few high-quality, large-scale datasets of patients with CLP are available. AI algorithms require diverse and representative datasets for training and validation, yet few such datasets are available [90,91], hampering the development and generalizability of AI models in CLP care. Furthermore, training AI models often inherit biases present in the input data, potentially leading to skewed clinical recommendations [91].…”

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products

“…Artificial intelligence is a branch of computer science that aims to simulate human thought processes, learning abilities, and knowledge reserves [38,39]. In recent decades, the improvement of computer speed and the rapid development of artificial intelligence (AI) have promoted the study of drug discovery and personalized medicine [40,41]. As one part of the development of personalized medicine, large-scale biomedical data were being used to identify the biological principles behind drugs to more accurately simulate and predict the complex effects of drug molecules in vivo [42].…”

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products

“…Artificial intelligence is a branch of computer science that aims to simulate human thought processes, learning abilities, and knowledge reserves [38,39]. In recent decades, the improvement of computer speed and the rapid development of artificial intelligence (AI) have promoted the study of drug discovery and personalized medicine [40,41]. As one part of the development of personalized medicine, large-scale biomedical data was being used to identify the biological principles behind drugs to more accurately simulate and predict the complex effects of drug molecules in vivo [42].…”